# Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

> **NCT00813293** · PHASE2 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Hepatocellular Cancer

## Interventions

- **DRUG:** Sorafenib
- **PROCEDURE:** radiofrequency ablation

## Key facts

- **NCT ID:** NCT00813293
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-06-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813293, "Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00813293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*